Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial

Background The role of surgery in the management of patients with advanced gastrointestinal stromal tumors (GIST) in the era of imatinib mesylate (IM) remains debated. We analyzed the outcome of patients with non metastatic locally advanced primary GIST treated with IM within the prospective BFR14 phase III trial.